$ZNTL News
Last published 2d ago
- 2d agoZNTLZentalis Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01
- 2d agoZNTLZentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireDENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROCDENALI Part 2c enrollment
- 1w agoZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib
- 1w agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib
- 2w agoZNTLZentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026GlobeNewswireMedian overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reportingMedian relative dose intensity was 84.6%,
- 3w agoZNTLZentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractGlobeNewswireMedian overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to be presented as a rapid oral presentation at ESMO Congress 2026 on
- 2mo agoZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib
- 2mo agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib
- 2mo agoZNTLZentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswireSAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL) ("Zentalis" or the "Company"), a clinical oncology innovator advancing late-stage development of an
- 2mo agoZNTLZentalis Pharmaceuticals Announces Pricing of Underwritten Public OfferingGlobeNewswireSAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL) ("Zentalis" or the "Company"), a clinical oncology innovator advancing late-stage development of an
- 3mo agoZNTLZentalis Pharmaceuticals Announces Proposed Underwritten Public OfferingGlobeNewswireSAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL) ("Zentalis" or the "Company"), a clinical oncology innovator advancing late-stage development of an
- 3mo agoZNTLZentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireFollowing U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2Enrollment completed in Part 2a and 2b of the DENALI trial; Part 2c is enrollingDENALI Part 2 topline
- 3mo agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib
- 3mo agoZNTLZentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026GlobeNewswireRapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology
- 5mo agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor
- 5mo agoZNTLZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial StrategyGlobeNewswireAppointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in Cyclin-E1 positive platinum-resistant ovarian cancer SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) --
- 5mo agoZNTLZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026GlobeNewswireIn an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen across all dose
- 6mo agoZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor
- 6mo agoZNTLZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical ProgressGlobeNewswire400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trialsDENALI Phase 2 trial topline readout
- 6mo agoZNTLZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian CancerGlobeNewswireGlobal Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval pathway, pending FDA
- 6mo agoZNTLZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor
- 6mo agoZNTLZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerGlobeNewswireSAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor
- 6mo agoZNTLZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026GlobeNewswirePreclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin E1-positive ovarian
- 7mo agoZNTLZentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian CancerGlobeNewswirePlanned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groupsAzenosertib therapeutic profile
- 7mo agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor
- 7mo agoZNTLZentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational UpdatesGlobeNewswireOn track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase 3, randomized,
- 8mo agoZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor
- 9mo agoZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor ConferenceGlobeNewswireSAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor
- 10mo agoONCYCGONZNTLAVBP+1Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026PR NewswireUSANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a...
- 1y agoZNTLZentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational ProgressGlobeNewswireDENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with
- 1y agoZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with
- 1y agoZNTLZentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate SecretaryGlobeNewswireSAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational ProgressGlobeNewswireDENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational ProgressGlobeNewswireFirst patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval,
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROCGlobeNewswirePhase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN
- 1y agoZNTLZentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual MeetingGlobeNewswireSAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for
- 1y agoZNTLZentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational UpdatesGlobeNewswirePositive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year
- 1y agoZNTLZentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025GlobeNewswireOne poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional
- 1y agoZNTLZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerGlobeNewswireAzenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective
- 1y agoZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for